Applications of new laboratory marker assays in neurological diagnoses - A pilot study

Stejskal, David; Vavrouskova, J.; Mareś, Jan; Urbánek, Karel

doi:10.5507/bp.2005.037

Cited by 3 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clusterin is also involved in immune regulation, lipid transport, sperm maturation and protection of cell membranes 5 . The results of experimental studies indicate the pathophysiologic importance of clusterin particularly in the pathogenesis of glomerulonephritis, polycystic kidneys, renal tubular diseases, neurodegenerative disorders, atherosclerosis, myocardial infarction and malignant tumors [5][6] . As the data are still sporadic and often contradictory, the aim of the present pilot study was to determine the changes in clusterin serum concentrations in oncologic patients who underwent a 3 week spa therapy.…”

Section: Introductionmentioning

confidence: 99%

Changes in Clusterin Serum Concentration Levels in Oncologic Patients During the Course of Spa Therapy - A Pilot Study

Vařeka¹,

Stejskal²,

Vařeková³

et al. 2009

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

Self Cite

View full text Add to dashboard Cite

Background: Clusterin (70-80 kDa; synonym ApoJ) is a stress-associated cytoprotective glycoprotein involved in many physiological and pathophysiological processes and it is up-regulated by various apoptotic triggers in many cancers and neurodegenerative diseases.Aim: Measurement of serum clusterin values in individuals with a history of cancer before and after spa therapy. Methods: Serum clusterin concentration (ELISA) was determined in a group of 26 oncologic patients (4 men and 22 women) at the beginning and at the end (the 18th or 19th day) of spa treatment. The spa treatment lasted 3 weeks. The patients with various types of cancer had undergone basic therapy (surgery, chemotherapy, actinotherapy) prior to spa treatment. They were divided according to the interval between the end of basic treatment and the start of spa therapy. Patients coming within 12 months comprised group A (n=15) while patients coming later comprised group B (n = 11).Results: clusterin concentrations increased in 11 patients (73 %) and decreased in 4 (27 %) in group A and increased in 5 (45 %) and decreased in 6 (55 %) in group B. The non-parametric sign test was non-significant. There were positive value of average change between the second and the first sample in group A and negative value in group B. In group A the parametric test showed significant increased clusterin concentration at the end of spa treatment but the data had non-parametric distribution in fact.Conclusion: It is concluded that early spa therapy increases clusterin serum concentration. This is probably due to to the positive effects of balneotherapy. However the sample was very small and further research is required.

show abstract

Section: Introductionmentioning

confidence: 99%

Changes in Clusterin Serum Concentration Levels in Oncologic Patients During the Course of Spa Therapy - A Pilot Study

Vařeka¹,

Stejskal²,

Vařeková³

et al. 2009

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

Self Cite

View full text Add to dashboard Cite

show abstract

CSF markers of neurodegeneration in Parkinson’s disease

et al. 2010

View full text Add to dashboard Cite

Parkinson's disease (PD) is a chronic, progressive, neurodegenerative disease with a multifactorial etiology. Protein accumulation is speculated by some to play a prominent role in the pathogenesis of PD. The severity of neurodegeneration should correlate with cerebrospinal fluid (CSF) levels of these neurodegenerative markers (NDMs). The aims of the study were to assess the CSF levels of tau protein, beta-amyloid (1-42), cystatin C, and clusterin in patients suffering from PD and in a control group, to compare the CSF levels between the two groups and to correlate them to PD duration. NDMs in the CSF were assessed in 32 patients suffering from PD and in a control group (CG) of 30 patients. The following statistically significant differences in the CSF were found: higher tau protein (p = 0.045) and clusterin levels (p = 0.004) in PD patients versus CG; higher tau protein levels (p = 0.033), tau protein/beta-amyloid (1-42) ratio (p = 0.011), and clusterin (p = 0.044) in patients suffering from PD for <2 years versus patients suffering PD for more than 2 years. No differences between beta-amyloid (1-42) and cystatin C CSF levels were found in the CG and PD patients groups. Significantly higher tau protein and clusterin CSF levels in the group of PD patients with disease duration of <2 years probably reflect the fact that most neurodegenerative changes in PD patients occur in the initial stage of disease.

show abstract

Tau protein and beta-amyloid1-42 CSF levels in different phenotypes of Parkinson’s disease

et al. 2011

View full text Add to dashboard Cite

Parkinson's disease (PD) is a neurodegenerative disorder with highly heterogeneous clinical manifestations. This fact has prompted many attempts to divide PD patients into clinical subgroups. This could lead to a better recognition of pathogenesis, improving targeted treatment and the prognosis of PD patients. The aim of the present study was to obtain cerebrospinal fluid (CSF) samples in PD patients and to search for a relationship between neurodegenerative CSF markers (tau protein, beta-amyloid(1-42) and index tau protein/beta-amyloid(1-42)) and the clinical subtypes. PD patients were divided into three subgroups: early disease onset (EDO), tremor-dominant PD (TD-PD), and non-tremor dominant PD (NT-PD) according to the previously published classification. Neurodegenerative markers in the CSF were assessed in these three groups of patients suffering from PD (EDO-17, TD-15, NT-16 patients) and in a control group (CG) of 19 patients suffering from non-degenerative neurological diseases and 18 patients with Alzheimer's disease (AD). The NT-PD patients were found to have significantly higher levels of CSF tau protein and index tau/beta than the control subjects and other Parkinsonian subgroups, but no significant differences in these markers were found between AD and NT-PD patients. In the context of more rapid clinical progression and more pronounced neuropathological changes in the NT-PD patient group, our results corroborate the opinion that CSF level of tau protein may be regarded as a potential laboratory marker of the presence and severity of neurodegeneration.

show abstract

Applications of new laboratory marker assays in neurological diagnoses - A pilot study

Cited by 3 publications

References 5 publications

Changes in Clusterin Serum Concentration Levels in Oncologic Patients During the Course of Spa Therapy - A Pilot Study

Changes in Clusterin Serum Concentration Levels in Oncologic Patients During the Course of Spa Therapy - A Pilot Study

CSF markers of neurodegeneration in Parkinson’s disease

Tau protein and beta-amyloid1-42 CSF levels in different phenotypes of Parkinson’s disease

Contact Info

Product

Resources

About